7Baggers
 A activity - Weekly Trend Summary & Technical Entry and Exit Tips  newser.com Tue, 18 Nov 2025 03:55:08 GMT
 NextCure secures $21.5 million in private placement to extend cash runway  Investing.com Nigeria Mon, 17 Nov 2025 19:03:29 GMT
 NextCure announces closing of $21.5M PIPE financing  TipRanks Mon, 17 Nov 2025 15:14:11 GMT
 NextCure Raises $21.5M in Private Placement  TipRanks Mon, 17 Nov 2025 13:47:17 GMT
 NextCure Announces Closing of $21.5 Million PIPE Financing  GlobeNewswire Mon, 17 Nov 2025 13:00:00 GMT
 NextCure: A High-Stakes Investment Opportunity  Ad-hoc-news.de Sat, 15 Nov 2025 08:21:04 GMT
 NextCure raises $21.5 million in private placement to fund ADC programs  Investing.com Nigeria Thu, 13 Nov 2025 05:29:52 GMT
 NextCure prices 2.5M shares at $8.52 in private placement  TipRanks Thu, 13 Nov 2025 00:31:55 GMT
 NextCure raises $21.5 million in private placement to fund ADC programs By Investing.com  Investing.com South Africa Wed, 12 Nov 2025 13:23:23 GMT
 nextcure sharpened r&d spending and narrowed its quarterly loss  Finimize Fri, 07 Nov 2025 20:40:54 GMT
 Ladenburg Thalmann Upgrades NextCure (NXTC)  Nasdaq Fri, 07 Nov 2025 18:49:00 GMT
 nextcure upgraded to buy from neutral at ladenburg  TipRanks Fri, 07 Nov 2025 14:01:48 GMT
 what is nextcure inc (nxtc) price targets?  fostersleader.com Fri, 07 Nov 2025 14:00:00 GMT
 NextCure Sharpened R&D Spending And Narrowed Its Quarterly Loss  Finimize Thu, 06 Nov 2025 08:23:50 GMT
 nextcure advances cancer therapies amid financial adjustments  TipRanks Thu, 06 Nov 2025 05:33:55 GMT
 nextcure reports q3 eps ($3.22), consensus ($3.98)  TipRanks Thu, 06 Nov 2025 03:21:47 GMT
 NextCure Advances Cancer Therapies Amid Financial Adjustments  TipRanks Wed, 05 Nov 2025 08:00:00 GMT

NextCure, Inc
(NASDAQ:NXTC) 

NXTC stock logo

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment o...

IPO Price: $15 (May 08, 2019)
Full Time Employees: 69
CEO: Michael S. Richman  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends